Publication:
Controlled Drug Release Systems for Cerebrovascular Diseases

Simple item page
dc.contributor.authorCelia Martín‐Morales
dc.contributor.authorSofia Caspani
dc.contributor.authorManuel Desco
dc.contributor.authorCélia Tavares de Sousa
dc.contributor.authorMaría Victoria Gómez‐Gaviro
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderComunidad de Madrid (España)
dc.contributor.funderFundación ProCNIC
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España)
dc.date.accessioned2024-12-20T11:43:38Z
dc.date.available2024-12-20T11:43:38Z
dc.date.issued2024-10-08
dc.description.abstractThis review offers a comprehensive exploration of optimized drug delivery systems tailored for controlled release and their crucial role in addressing cerebrovascular diseases. Through an in-depth analysis, various controlled release methods, including nanoparticles, liposomes, hydrogels, and other emerging technologies are examined. Highlighting the importance of precise drug targeting, it is delved into the underlying mechanisms of these delivery systems and their potential to improve therapeutic outcomes while minimizing adverse effects. Additionally, the specific applications of these optimized drug delivery systems in treating cerebrovascular disorders such as ischemic stroke, cerebral aneurysms, and intracranial hemorrhage are discussed. By shedding light on the advancements in drug delivery techniques and their implications in cerebrovascular medicine, this review offers valuable insights into the future of therapeutic interventions in neurology.
dc.description.peerreviewedSí
dc.description.sponsorshipC.T.e.S. and M.V.G.-G. contributed equally to this work. This researchwas funded by the Ministerio de Ciencia, Innovación y Universidadesco-financed by the European Regional Development Fund, “A Way ofmaking Europe” initiative. Grant PLEC2022-009235 funded by MICIU/AEI /10.13039/501100011033 and by the “European Union NextGener-ation EU/ PRTR. Grant PID2022-141080OB-C21 funded by MICIU/AEI/10.13039/501100011033 and by FEDER, UE. This study has been fundedby Instituto de Salud Carlos III (ISCIII) through the project “DTS22/00030”and co-funded by the European Union. This work was partially supported by Comunidad de Madrid, project (S2022/BMD-7403 RENIM-CM). TheCNIC is supported by the Ministerio de Ciencia, Innovación y Universi-dades and the Pro CNIC Foundation and is a Severo Ochoa Centre of Excel-lence (SEV-2015-0505). CTS acknowledges the program Atraccion de Tal-ento (CAM), ref. 2020-T1/IND-1988. The cover has been supported by Co-munidad de Madrid, project (S2022/BMD-7403 RENIM-CM) and by GrantPID2022-141080OB-C21 funded by MICIU/AEI /10.13039/501100011033and by FEDER, UE.”
dc.identifier.citationAdvanced Therapeutics, 2024 doi: 10.1002/adtp.202400239
dc.identifier.doi10.1002/adtp.202400239
dc.identifier.issn2366-3987
dc.identifier.journalAdvanced Therapeutics
dc.identifier.urihttps://hdl.handle.net/20.500.12105/25929
dc.language.isoeng
dc.publisherWiley
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PID2022-141080OB-C21
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/MICIU/AEI/10.13039/501100011033
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/DTS22/00030
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/S2022/BMD-7403/RENIM-CM
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SEV-2015-0505
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/2020-T1/IND-1988
dc.relation.publisherversionhttps://doi.org/10.1002/adtp.202400239
dc.repisalud.institucionCNIC
dc.repisalud.orgCNICCNIC::Unidades técnicas::Imagen Avanzada
dc.rights.accessRightsopen access
dc.rights.licenseAttribution-NonCommercial-ShareAlike 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.titleControlled Drug Release Systems for Cerebrovascular Diseases
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isFunderOfPublication1aef4c3b-1ee5-4534-83b4-3f3811c67280
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationc87c70a3-e023-4b6b-ac25-1b2d1b483786
relation.isFunderOfPublicationef935eeb-4c46-446a-868e-66e905683e75
relation.isFunderOfPublication9bec53f6-b1d2-4340-9f6b-91815956d602
relation.isFunderOfPublication.latestForDiscovery1aef4c3b-1ee5-4534-83b4-3f3811c67280
relation.isPublisherOfPublicationd81e762a-95f7-4917-88a1-8004b3b8caa7
relation.isPublisherOfPublication.latestForDiscoveryd81e762a-95f7-4917-88a1-8004b3b8caa7

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Controlled Drug Release_ADVANCED THERAPEUTICS_2024.pdf
Size:
1.85 MB
Format:
Adobe Portable Document Format
Download

Collections

Grupos de investigación